Received Jul 18, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | ZK9P4 | — |
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | — | — |
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | — | — |
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | EK7DG | — |
Double dose on same day; This non-serious case was reported by a nurse via call center representative and described the occurrence of accidental overdose in a 17-year-old male patient who received Men B NVS (Bexsero) (batch number ZK9P4) for prophylaxis. Co-suspect products included Men ACWY-CRM NVS (Menveo) (batch number EK7DG) for prophylaxis, Men B NVS (Bexsero) for prophylaxis and Men ACWY-CRM NVS (Menveo) for prophylaxis. On 23-JUN-2025, the patient received Bexsero, Menveo, Bexsero and Menveo. On 23-JUN-2025, an unknown time after receiving Bexsero, Menveo, Bexsero and Menveo, the patient experienced accidental overdose (Verbatim: Double dose on same day). The outcome of the accidental overdose was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 09-JUL-2025 and 11-JUL-2025 The reporter had a patient that, on the date of the visit, inadvertently received the Menveo 1 vial, they received 2 doses on the same day. They also received the Bexsero. So, on that day, they received a double, 2 of each on the same day. The healthcare professional informed that on the same day on 23rd June 2025 the patient received 2 doses of Menveo (1 vial) and 2 doses of Bexsero, in total, the patient received 4 doses which led to accidental overdose.